演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

子宮頸癌同時化学放射線療法に対するオランザピン併用療法の後方視的検討

演題番号 : P94-5

[筆頭演者]
演者)笠松 由佳:1 
[共同演者]
安部 正和:1、角 暢浩:1、吉岡 恵美:1、望月 亜矢子:1、高橋 伸卓:1、武隈 宗孝:1、平嶋 泰之:1

1:静岡県立静岡がんセンター・婦人科

 

Introduction: GAND-emesis study revealed the efficacy of triplet antiemetic therapy (palonosetron, fosaprepitant, and dexamethasone) in patients receiving radiotherapy and concomitant weekly cisplatin. But the proportion of patients with sustained no emesis was 65%. Olanzapine is proved to be effective for chemotherapy-induced nausea and vomiting. But its efficacy in combination with triplet antiemetic therapy for chemoradiotherapy combined with low dose weekly cisplatin is unknown.

Objective: The aim of this retrospective study is to evaluate the preventive effect of olanzapine for the prevention of nausea and vomiting caused by 6 cycles of weekly cisplatin combined with pelvic radiotherapy when used with triplet antiemetic therapy.

Method: Cervical cancer patients receiving pelvic radiotherapy and weekly cisplatin (30-40mg/m2) who had grade 2 or 3 nausea in prior cycle despite triplet antiemetic therapy were assigned to this study. From the next cycles to cycles in which patients developed grade 2 or 3 nausea, they received 5mg of olanzapine combined with triplet antiemetic therapy for 7 days. The effectiveness of preventive administration of olanzapine was evaluated retrospectively.

Results: Twenty-one patients were evaluable. The nausea control rate, defined as nausea grade 0 or 1, was improved from 0% to 90% (p<0.01). The vomiting rate decreased from 52% to 10% (p<0.05). The rescue usage rate decreased from 95% to 43% (p<0.05). There were no grade 3-4 adverse events.

Conclusion: Preventive use and safety of olanzapine combined with triplet antiemetic therapy showed improvement in control of refractory nausea in patients receiving radiotherapy and concomitant weekly cisplatin.

キーワード

臓器別:子宮

手法別:支持療法

前へ戻る